Skip to Content
Merck

UHPLC Analysis of Iloperidone and Its Primary Metabolite Hydroxyiloperidone on Ascentis® Express C18

UHPLC Analysis of Iloperidone and Its Primary Metabolite Hydroxyiloperidone on Ascentis® Express C18 application for UHPLC

Materials

analytical column

Product No.
Description
Pricing

Ascentis® Express C18, 2 μm UHPLC Column

2 μm particle size, L × I.D. 10 cm × 3 mm

mobile phase component

Product No.
Description
Pricing

Ammonium formate

eluent additive for LC-MS, LiChropur, ≥99.0%

CONDITIONS

column

Ascentis Express C18, 10 cm x 3.0 mm, I.D., 2.0 μm particles (50819-U)

mobile phase

[A] 10 mM ammonium formate in water, pH adjusted to 3.0 with formic acid [B] 0.1% formic acid in methanol

gradient

45% B for 2 min; to 80% B over 10 min; held at 80% B for 2 min

flow rate

0.5 mL/min

pressure

6500 psi (445 bar)

column temp.

35 °C

detector

UV, 275 nm

injection

2 μL

sample

50 μg/mL Iliperidone, 5 μg/mL hydroxyiliperidone in 10% methanol

Description

Analysis Note

Iloperidone is an atypical antipsychotic administered for the treatment of schizophrenia. The drug is marketed under the trade names Fanapt and Fanapta. Hydroxyiloperidone is a major metabolite of iloperidone. The metabolite is also pharmacologically active, possessing central nervous system (CNS) activity. Shown here is the rapid, efficient UHPLC separation of iloperidone and hydroxyiloperidone on a Fused-Core Ascentis Express C18 column. Cerilliant CRMs provided reliable quantification.

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany